U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06853171) titled 'Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric Disorders' on Feb. 25.

Brief Summary: This study is designed to assess the safety, tolerability, and pharmacokinetics (PK) of multiple doses and ratios of xanomeline and trospium chloride in an IR capsule (KarXT) and dual-burst release of xanomeline with immediate-release trospium chloride in adolescents with psychiatric disorders.

Study Start Date: April 29

Study Type: INTERVENTIONAL

Condition: Psychiatric Disorders

Intervention: DRUG: KarXT

Specified dose on specif...